Current prostate cancer hormonal therapies work by either depleting levels of androgen, inhibiting the synthesis of androgens, or by preventing androgen from binding to the androgen receptor (AR). However, prolonged treatment to current therapies can render cancer resistant to existing therapies over time.
ESSA has developed a new class of drugs called anitens that block a novel target on the AR, the N-terminal domain. The N-terminal domain controls the transcriptional activity of the AR. This domain is critical for AR function and is not currently targeted by any other therapy. By blocking AR-directed biology in this manner, resistance to current hormone therapies may be overcome.